FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review
Abdel-Aziz, Amal Kamal; Dokla, Eman M E; Saadeldin, Mona Kamal;
Abstract
FMS-like tyrosine kinase 3 (FLT3) mutations occur in almost 30% of acute myeloid leukemia (AML) patients. Despite the initial clinical efficacy of FLT3 inhibitors, many treated AML patients with mutated FLT3 eventually relapse. This review critically discusses the opportunities and challenges of FLT3-targeted therapies and sheds light on their drug interactions as well as potential biomarkers. Furthermore, we focus on the molecular mechanisms underlying the resistance of FLT3 internal tandem duplication (FLT3-ITD) AMLs to FLT3 inhibitors alongside novel therapeutic strategies to reverse resistance. Notably, dynamic heterogeneous patterns of clonal selection and evolution contribute to the resistance of FLT3-ITD AMLs to FLT3 inhibitors. Ongoing preclinical research and clinical trials are actively directed towards devising rational "personalized" or "patient-tailored" combinatorial therapeutic regimens to effectively treat patients with FLT3 mutated AML.
Other data
| Title | FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review | Authors | Abdel-Aziz, Amal Kamal ; Dokla, Eman M E; Saadeldin, Mona Kamal | Keywords | AML; Biomarker; Drug interaction; FLT3 mutation; Resistance; Toxicity | Issue Date | Nov-2023 | Journal | Critical reviews in oncology/hematology | ISSN | 10408428 | DOI | 10.1016/j.critrevonc.2023.104139 | PubMed ID | 37717880 | Scopus ID | 2-s2.0-85172274952 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.